
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1531556/publications.pdf Version: 2024-02-01



C. RRANDON GUNN

#	Article	IF	CITATIONS
1	Late dysphagia after radiotherapyâ€based treatment of head and neck cancer. Cancer, 2012, 118, 5793-5799.	2.0	284
2	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 782.	3.4	185
3	Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology, 2020, 6, 1397.	3.4	183
4	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. Radiotherapy and Oncology, 2016, 120, 48-55.	0.3	177
5	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF^{V600E}</i> -Mutated Anaplastic Thyroid Carcinoma. Thyroid, 2019, 29, 1036-1043.	2.4	156
6	Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. , 2018, 6, 68.		148
7	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. International Journal of Radiation Oncology Biology Physics, 2014, 89, 846-853.	0.4	128
8	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 96, 30-41.	0.4	123
9	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.4	121
10	Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid, 2017, 27, 672-681.	2.4	111
11	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid, 2018, 28, 945-951.	2.4	111
12	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventoryâ€Head and Neck Module. Cancer, 2014, 120, 1975-1984.	2.0	106
13	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiotherapy and Oncology, 2014, 112, 321-325.	0.3	96
14	Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. Scientific Reports, 2018, 8, 1524.	1.6	95
15	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 204-209.	0.4	94
16	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 360-367.	0.4	88
17	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose–volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiotherapy and Oncology, 2016, 118, 304-314.	0.3	85
18	Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. Journal of Oncology Practice, 2016, 12, 511-518.	2.5	81

#	Article	IF	CITATIONS
19	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiotherapy and Oncology, 2016, 121, 381-386.	0.3	78
20	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. International Journal of Particle Therapy, 2015, 2, 19-28.	0.9	76
21	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiotherapy and Oncology, 2017, 123, 401-405.	0.3	73
22	Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 235-242.	0.4	72
23	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiotherapy and Oncology, 2017, 124, 232-239.	0.3	69
24	Patterns of Locoregional Failure After Exclusive IMRT for Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, 737-746.	0.4	67
25	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Medical Dosimetry, 2016, 41, 189-194.	0.4	62
26	Weekly Dose–Volume Parameters of Mucosa and Constrictor Muscles Predict the Use of Percutaneous Endoscopic Gastrostomy During Exclusive Intensity-Modulated Radiotherapy for Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 52-59.	0.4	61
27	Quality Assurance Assessment of Diagnostic and Radiation Therapy–Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interest–based Comparison of Rigid and Deformable Algorithms. Radiology, 2015, 274, 752-763.	3.6	58
28	Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head and Neck, 2017, 39, 1671-1679.	0.9	57
29	Late radiation-associated dysphagia (late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: A preliminary dosimetric comparison. Oral Oncology, 2014, 50, 746-752.	0.8	56
30	The symptom burden of treatmentâ€naive patients with head and neck cancer. Cancer, 2015, 121, 766-773.	2.0	56
31	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer, 2017, 123, 1653-1661.	2.0	55
32	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 111, 281-288.	0.3	54
33	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 532-540.	0.4	54
34	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR in Biomedicine, 2015, 28, 1645-1654.	1.6	51
35	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 1053.	1.2	51
36	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Scientific Data, 2018, 5, 180173.	2.4	51

#	Article	IF	CITATIONS
37	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer, 2013, 119, 3162-3169.	2.0	49
38	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. International Journal of Radiation Oncology Biology Physics, 2016, 95, 344-352.	0.4	49
39	High symptom burden prior to radiation therapy for head and neck cancer: A patientâ€reported outcomes study. Head and Neck, 2013, 35, 1490-1498.	0.9	48
40	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. International Journal of Radiation Oncology Biology Physics, 2019, 104, 724-733.	0.4	47
41	Long-Term, Prospective Performance of the MDÂAnderson Dysphagia Inventory in "Low-Intermediate Risk―Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 700-708.	0.4	46
42	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247.	1.1	41
43	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	0.9	41
44	Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1244.	1.2	39
45	Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Quality of Life Research, 2013, 22, 2331-2339.	1.5	38
46	Symptom burden as a driver of decisional regret in longâ€ŧerm oropharyngeal carcinoma survivors. Head and Neck, 2017, 39, 2151-2158.	0.9	38
47	Head and neck surgical oncology in the time of a pandemic: Subsiteâ€specific triage guidelines during the <scp>COVID</scp> â€19 pandemic. Head and Neck, 2020, 42, 1194-1201.	0.9	38
48	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope, 2017, 127, 842-848.	1.1	37
49	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head and Neck, 2016, 38, E1472-80.	0.9	36
50	Conformal Radiotherapy of the Dominant Liver Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 562-567.	0.6	35
51	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. Radiation Oncology, 2016, 11, 95.	1.2	34
52	Longâ€ŧerm outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	0.9	33
53	Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury. Scientific Reports, 2016, 6, 29864.	1.6	33
54	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head and Neck, 2016, 38, E452-8.	0.9	32

#	Article	IF	CITATIONS
55	Improved setup and positioning accuracy using a threeâ€point customized cushion/mask/biteâ€block immobilization system for stereotactic reirradiation of head and neck cancer. Journal of Applied Clinical Medical Physics, 2016, 17, 180-189.	0.8	32
56	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiotherapy and Oncology, 2017, 124, 248-255.	0.3	32
57	Design and fabrication of a 3D–printed oral stent for head and neck radiotherapy from routine diagnostic imaging. 3D Printing in Medicine, 2017, 3, 12.	1.7	31
58	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology, 2019, 3, 22.	2.3	31
59	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer, 2020, 20, 912.	1.1	31
60	Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head and Neck, 2012, 34, 1255-1262.	0.9	30
61	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiation Oncology, 2019, 14, 148.	1.2	30
62	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. Oral Oncology, 2016, 61, 62-69.	0.8	29
63	Effects of radiation on the temporal bone in patients with head and neck cancer. Head and Neck, 2016, 38, 1428-1435.	0.9	29
64	Prognostic value of p16 expression in Epsteinâ€Barr virus–positive nasopharyngeal carcinomas. Head and Neck, 2016, 38, E1459-66.	0.9	28
65	Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram. Scientific Reports, 2017, 7, 43928.	1.6	28
66	Radiotherapy dose–volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. Radiotherapy and Oncology, 2018, 128, 442-451.	0.3	28
67	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer, 2019, 125, 1823-1829.	2.0	28
68	Management of the lymph nodeâ€positive neck in the patient with human papillomavirusâ€associated oropharyngeal cancer. Cancer, 2014, 120, 3082-3088.	2.0	27
69	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clinical and Translational Radiation Oncology, 2018, 11, 11-18.	0.9	27
70	Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis. Oral Oncology, 2017, 66, 75-80.	0.8	26
71	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26
72	Late radiationâ€associated dysphagia with lower cranial neuropathy in longâ€ŧerm oropharyngeal cancer survivors: Video case reports. Head and Neck, 2015, 37, E56-62.	0.9	25

#	Article	lF	CITATIONS
73	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65Âyears old. Radiation Oncology, 2017, 12, 150.	1.2	25
74	Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry. Oral Oncology, 2019, 91, 13-20.	0.8	25
75	Outcomes of carotidâ€sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	1.1	25
76	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. Clinical and Translational Radiation Oncology, 2019, 18, 16-22.	0.9	24
77	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clinical and Translational Radiation Oncology, 2019, 18, 120-127.	0.9	24
78	Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 1066.	1.2	23
79	Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. Chinese Clinical Oncology, 2016, 5, 54-54.	0.4	23
80	Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head and Neck, 2017, 39, 1291-1295.	0.9	22
81	Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid, 2021, 31, 1235-1243.	2.4	22
82	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiotherapy and Oncology, 2015, 117, 132-138.	0.3	21
83	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose–response characterization of quantitative signal kinetics. Radiotherapy and Oncology, 2016, 118, 315-322.	0.3	21
84	Singleâ€item discrimination of qualityâ€ofâ€life–altering dysphagia among 714 longâ€term oropharyngeal cancer survivors: Comparison of patientâ€reported outcome measures of swallowing. Cancer, 2019, 125, 1654-1664.	2.0	21
85	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiotherapy and Oncology, 2020, 142, 133-139.	0.3	21
86	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiotherapy and Oncology, 2020, 148, 258-266.	0.3	21
87	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. Practical Radiation Oncology, 2013, 3, 186-193.	1.1	20
88	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiotherapy and Oncology, 2020, 148, 252-257.	0.3	20
89	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiotherapy and Oncology, 2018, 126, 75-80.	0.3	19
90	Radiographic retropharyngeal lymph node involvement in HPVâ€associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer, 2019, 125, 1536-1546.	2.0	19

#	Article	IF	CITATIONS
91	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2014, 151, 619-626.	1.1	18
92	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	0.9	18
93	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2017, 7, 28-35.	0.9	18
94	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensityâ€modulated radiation therapy. Cancer, 2018, 124, 1415-1427.	2.0	18
95	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1029-1035.	0.4	18
96	Modeling symptom drivers of oral intake in long-term head and neck cancer survivors. Supportive Care in Cancer, 2019, 27, 1405-1415.	1.0	18
97	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiotherapy and Oncology, 2020, 145, 95-100.	0.3	18
98	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiotherapy and Oncology, 2021, 160, 32-39.	0.3	18
99	Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Research, 2018, 7, 87.	0.8	18
100	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. International Journal of Radiation Oncology Biology Physics, 2022, 113, 426-436.	0.4	18
101	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus–associated oropharyngeal cancer. Cancer, 2016, 122, 1702-1707.	2.0	17
102	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. International Journal of Cancer, 2016, 138, 1290-1297.	2.3	17
103	Longâ€ŧerm quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope, 2020, 130, 86-93.	1.1	17
104	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. British Journal of Cancer, 2021, 124, 628-633.	2.9	17
105	Self-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center. Supportive Care in Cancer, 2021, 29, 1825-1835.	1.0	17
106	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. Clinical and Translational Radiation Oncology, 2018, 12, 40-46.	0.9	16
107	Quantifying the accuracy of deformable image registration for coneâ€beam computed tomography with a physical phantom. Journal of Applied Clinical Medical Physics, 2019, 20, 92-100.	0.8	16
108	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. Radiotherapy and Oncology, 2019, 133, 35-42.	0.3	16

#	Article	lF	CITATIONS
109	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. International Journal of Particle Therapy, 2016, 2, 533-543.	0.9	16
110	Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. International Journal of Endocrine Oncology, 2016, 3, 221-233.	0.4	15
111	Decreased gastrostomy tube incidence and weight loss after transoral robotic surgery for low†to intermediateâ€risk oropharyngeal squamous cell carcinoma. Head and Neck, 2018, 40, 2507-2513.	0.9	15
112	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching â€ĩliquid biopsy' and quantitative tumor modeling. BMC Cancer, 2018, 18, 903.	1.1	14
113	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. Radiotherapy and Oncology, 2019, 130, 46-55.	0.3	14
114	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. Advances in Radiation Oncology, 2020, 5, 111-119.	0.6	14
115	Determinants of patientâ€reported xerostomia among longâ€term oropharyngeal cancer survivors. Cancer, 2021, 127, 4470-4480.	2.0	14
116	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organsâ€atâ€risk margination using daily CT onâ€rails imaging. Journal of Applied Clinical Medical Physics, 2015, 16, 159-169.	0.8	13
117	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. Oral Oncology, 2015, 51, 195-201.	0.8	13
118	Evaluation of the accuracy of deformable image registration on MRI with a physical phantom. Journal of Applied Clinical Medical Physics, 2020, 21, 166-173.	0.8	13
119	A Phase I/II Study of Altered Fractionated IMRT Alone for Intermediate T-Stage Oropharyngeal Carcinoma. Strahlentherapie Und Onkologie, 2010, 186, 489-495.	1.0	12
120	Characterization of a new physical phantom for testing rigid and deformable image registration. Journal of Applied Clinical Medical Physics, 2019, 20, 145-153.	0.8	12
121	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer, 2020, 28, 261-269.	1.0	12
122	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 185-193.	0.4	12
123	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Advances in Radiation Oncology, 2020, 5, 567-572.	0.6	12
124	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncology, 2021, 113, 105125.	0.8	12
125	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiotherapy and Oncology, 2021, 159, 21-27.	0.3	12
126	Lyman–Kutcher–Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiotherapy and Oncology, 2020, 146, 200-204.	0.3	12

#	Article	IF	CITATIONS
127	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clinical and Translational Radiation Oncology, 2020, 24, 71-78.	0.9	11
128	Outcomes after radiation therapy for <scp>T2N0</scp> /stage <scp>II</scp> glottic squamous cell carcinoma. Head and Neck, 2020, 42, 2791-2800.	0.9	11
129	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiotherapy and Oncology, 2020, 148, 133-139.	0.3	11
130	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Current Treatment Options in Oncology, 2021, 22, 54.	1.3	11
131	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 319-327.	0.9	11
132	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1496-1504.	0.4	11
133	Orbital carcinomas treated with adjuvant intensityâ€modulated radiation therapy. Head and Neck, 2016, 38, E580-7.	0.9	10
134	The First Reported Case of Primary Intestinal-type Adenocarcinoma of the Middle Ear and Review of the Literature. Otology and Neurotology, 2017, 38, e364-e368.	0.7	10
135	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiotherapy and Oncology, 2020, 151, 119-125.	0.3	10
136	Osteoradionecrosis in patients with salivary gland malignancies. Oral Oncology, 2016, 57, 1-5.	0.8	9
137	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Physics and Imaging in Radiation Oncology, 2020, 14, 1-5.	1.2	9
138	Non-English language validation of patient-reported outcome measures in cancer clinical trials. Supportive Care in Cancer, 2020, 28, 2503-2505.	1.0	9
139	Role of induction chemotherapy for oral cavity squamous cell carcinoma. Cancer, 2021, 127, 3107-3112.	2.0	9
140	Advances in Radiation Oncology for the Management of Oropharyngeal Tumors. Otolaryngologic Clinics of North America, 2013, 46, 629-643.	0.5	8
141	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. Cancers of the Head & Neck, 2019, 4, 4.	6.2	8
142	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer, 2020, 126, 749-756.	2.0	8
143	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Advances in Radiation Oncology, 2020, 5, 929-935.	0.6	8
144	Computed Tomography Radiomics Kinetics as Early Imaging Correlates of Osteoradionecrosis in Oropharyngeal Cancer Patients. Frontiers in Artificial Intelligence, 2021, 4, 618469.	2.0	8

#	Article	IF	CITATIONS
145	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. International Journal of Particle Therapy, 2021, 8, 108-118.	0.9	8
146	Nasopharyngeal Carcinoma Metastasis to the Pituitary Gland: A Case Report and Literature Review. Journal of Neuro-Oncology, 2004, 68, 87-90.	1.4	7
147	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. Oral Oncology, 2016, 63, 16-22.	0.8	7
148	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, 638-644.	0.4	7
149	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. Advances in Radiation Oncology, 2020, 5, 1359-1363.	0.6	7
150	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology, 2018, 79, 1-8.	0.8	6
151	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. Journal of Neurosurgery, 2019, 130, 812-821.	0.9	6
152	Transitioning from measurement-based to combined patient-specific quality assurance for intensity-modulated proton therapy. British Journal of Radiology, 2020, 93, 20190669.	1.0	6
153	Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center. JCO Oncology Practice, 2020, 16, e1067-e1077.	1.4	6
154	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. Oral Oncology, 2020, 106, 104665.	0.8	6
155	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. Scientific Data, 2020, 7, 63.	2.4	6
156	18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2021, 29, 93-101.	0.9	6
157	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	6
158	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. Head and Neck, 2014, 36, 819-825.	0.9	5
159	Cognitive function and patientâ€reported memory problems after radiotherapy for cancers at the skull base: A crossâ€sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventoryâ€Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	0.9	5
160	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clinical and Translational Radiation Oncology, 2020, 22, 98-105.	0.9	5
161	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 615.	1.2	5
162	Severe radiation therapy–related soft tissue toxicity in a patient with porphyria cutanea tarda: A literature review. Head and Neck, 2010, 32, 1112-1117.	0.9	4

#	Article	IF	CITATIONS
163	Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy. International Journal of Computer Assisted Radiology and Surgery, 2015, 10, 1667-1673.	1.7	4
164	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. Radiotherapy and Oncology, 2021, 157, 63-69.	0.3	4
165	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	0.9	4
166	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. International Journal of Particle Therapy, 2021, 8, 234-247.	0.9	4
167	Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers. International Journal of Particle Therapy, 2021, 8, 155-167.	0.9	4
168	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 374-382.	0.9	4
169	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Scientific Reports, 2022, 12, .	1.6	4
170	Evaluation of the high definition field of view option of a large-bore computed tomography scanner for radiation therapy simulation. Physics and Imaging in Radiation Oncology, 2020, 13, 44-49.	1.2	3
171	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Practical Radiation Oncology, 2020, 10, 363-371.	1.1	3
172	Combination Intensity Modulated Proton Therapy and Passive Scatter Boost for Rapidly Progressing Nasal Cavity Squamous Cell Carcinoma. Cureus, 2017, 9, e1685.	0.2	3
173	Proton Therapy in a Pandemic: An Operational Response to the COVID-19 Crisis. International Journal of Particle Therapy, 2020, 7, 54-57.	0.9	3
174	Association of hearing loss and tinnitus symptoms with <scp>healthâ€related</scp> quality of life among <scp>longâ€term</scp> oropharyngeal cancer survivors. Cancer Medicine, 0, , .	1.3	3
175	Complications of tympanostomy tubes in head and neck cancer patients. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2016, 37, 356-361.	0.6	2
176	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Physics and Imaging in Radiation Oncology, 2019, 10, 29-34.	1.2	2
177	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer, 2021, 127, 1228-1237.	2.0	2
178	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. International Journal of Particle Therapy, 2021, 8, 213-222.	0.9	2
179	Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 805-813.	2.3	2
180	Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. Balkan Medical Journal, 2016, 33, 339-343.	0.3	2

G BRANDON GUNN

#	ARTICLE	IF	CITATIONS
181	Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. , 2012, 3, 29-31.		2
182	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Scientific Reports, 2022, 12, 6662.	1.6	2
183	In Regard to Kjems etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 240.	0.4	1
184	Reply to radiotherapy for human papillomavirusâ€positive oropharyngeal cancers in the National Cancer Data Base. Cancer, 2016, 122, 3411-3412.	2.0	1
185	Feeding Tube Utilization in Patients with Salivary Gland Malignancies. Otolaryngology - Head and Neck Surgery, 2017, 156, 109-117.	1.1	1
186	Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clinical and Translational Radiation Oncology, 2021, 30, 78-83.	0.9	1
187	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. Acta OncolA³gica, 2022, 61, 146-152.	0.8	1
188	Analysis of Charges Associated with Definitive Nonsurgical Therapy for Early-Stage Lateralized Tonsil Cancer. Annals of Surgical Oncology, 2015, 22, 2755-2760.	0.7	0
189	Radiotherapy for Temporal Bone Cancers. , 2018, , 363-378.		Ο
190	Postoperative Intensity-Modulated Radiation Therapy for Head and Neck Cancers: A Case-Based Review. , 2015, , 193-213.		0